Canntab Therapeutics Files 11 Patent Applications Related to Pharmaceutical #Cannabis.
Canntab's portfolio now includes 11 patent applications in the United States and internationally. These filings, which include 7 non-provisional US patent application and 4 PCT patent applications, build on Canntab's growing intellectual property portfolio, which already included 7 provisional US patent applications and 10 trademark applications in the United States and Canada. The patent applications that were filed pertain to a variety of Canntab's innovative technologies related to oral dosage formulations of pharmaceutical cannabis, including:
* Sustained Release Cannabinoid Formulations;
* Immediate Release Cannabidiol Formulations;
* Modified-Release Multi-Layer Cannabinoid Formulations;
* Flash-Melt Cannabinoid Formulations; and
* Bi-layer Cannabinoid Tablets.
These patent applications are part of Canntab's concerted strategy to develop a comprehensive intellectual property portfolio which covers the company's technology and formulations related to pharmaceutical preparations which contain natural or synthetic cannabinoids. Canntab is currently developing a number of products which utilize this technology, which includes a variety of extended released tablets containing a mixture of THC (Tetrahydrocannabinol) and CBD (Cannabidiol) that can be used to treat a number of ailments, such as
* sleep disorders;
* post-traumatic stress disorder (PTSD);
* social anxiety;
* addiction;
* arthritis;
* general pain; and
* the pain management and appetite loss associated with cancer treatments.
QBL subsidiary MCL has exclusive distribution in Australia/Asia.
Here you have the opportunity to take advantage on facts and info from QBL. Like the ”QBL on ASX” chapter, who can provide verified facts; here is also regulated on-line stockbrokers suggestion, no games info and a good sum up. Voluntary suspension is requested regarding a significant and strategic acquisition by QBL’s subsidiary MEDICAL CANNABIS Limited until Friday 1 of june or before. Contact information to the QBL Investor service, who can reply on questions. https://www.queenslandbauxite.com/
(Australia other timezone)
Canntab's portfolio now includes 11 patent applications in the United States and internationally. These filings, which include 7 non-provisional US patent application and 4 PCT patent applications, build on Canntab's growing intellectual property portfolio, which already included 7 provisional US patent applications and 10 trademark applications in the United States and Canada. The patent applications that were filed pertain to a variety of Canntab's innovative technologies related to oral dosage formulations of pharmaceutical cannabis, including:
* Sustained Release Cannabinoid Formulations;
* Immediate Release Cannabidiol Formulations;
* Modified-Release Multi-Layer Cannabinoid Formulations;
* Flash-Melt Cannabinoid Formulations; and
* Bi-layer Cannabinoid Tablets.
These patent applications are part of Canntab's concerted strategy to develop a comprehensive intellectual property portfolio which covers the company's technology and formulations related to pharmaceutical preparations which contain natural or synthetic cannabinoids. Canntab is currently developing a number of products which utilize this technology, which includes a variety of extended released tablets containing a mixture of THC (Tetrahydrocannabinol) and CBD (Cannabidiol) that can be used to treat a number of ailments, such as
* sleep disorders;
* post-traumatic stress disorder (PTSD);
* social anxiety;
* addiction;
* arthritis;
* general pain; and
* the pain management and appetite loss associated with cancer treatments.
QBL subsidiary MCL has exclusive distribution in Australia/Asia.
Here you have the opportunity to take advantage on facts and info from QBL. Like the ”QBL on ASX” chapter, who can provide verified facts; here is also regulated on-line stockbrokers suggestion, no games info and a good sum up. Voluntary suspension is requested regarding a significant and strategic acquisition by QBL’s subsidiary MEDICAL CANNABIS Limited until Friday 1 of june or before. Contact information to the QBL Investor service, who can reply on questions. https://www.queenslandbauxite.com/
(Australia other timezone)
Robert
